EXAS - Exact Sciences patent infringement case against Geneoscopy to proceed
2024-05-21 10:36:37 ET
More on Exact Sciences
- Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
- Most attractive short-term overwriting stocks for June expiration - Goldman
- Exact Sciences down 17% on quarterly bottom line miss, maintaining 2024 guidance
- Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript
- Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript